Profiling the cancer genome to optimize the management of solid tumors
Accurate detection of molecular signatures associated with solid tumors is difficult. It requires multiple cytogenetic and molecular assays that can be costly and time-consuming.1
Three solutions tailored to your needs
1:Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection.Phillip N. Gray,*Charles L.M. Dunlop et al. Cancers (Basel). 2015 Sep; 7(3): 1313–1332.
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
SOPHiA Solid Tumor Solution is a CE-IVD products for Europe only. All other products including the SOPHiA DDM platform provided in Europe are Research Use Only.